We have shown that subsets present in a refractory AML display increased expression of CD34, CD38, and CD184 while viSNE analysis showed that these cells “moved away” phenotypically from healthy stem cells and the bulk of the original disease. This evidence concerns the gene CD34 and acute myeloid leukemia.